Weight Change in Patients with Type 2 Diabetes Starting Basal Insulin Therapy: Correlates and Impact on Outcomes

References

• . Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90(1):493–500
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Rubin RR, Lauritzen T,. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673–2679
   PubMed Web of Science ®Google Scholar
• . Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543–2545
   PubMed Web of Science ®Google Scholar
• . Larkin ME, Capasso VA, Chen CL,. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34(3):511–517
   Google Scholar
• . Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27( Suppl 3):13–20
   PubMed Web of Science ®Google Scholar
• . Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:2–9
   Google Scholar
• . Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. http://diabetes.niddk.nih.gov/dm/pubs/statistics/DM_Statistics_508.pdf. Accessed June 15, 2014
   Google Scholar
• . Wong K, Glovaci D, Malik S,. Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification. J Diabetes Complications. 2012;26(3):169–174
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB,. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Abrahamson MJ, Barzilay JI,. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement–executive summary. Endocr Pract. 2013;19(3):536–557
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes. Diabetes Care. 2001;24(10):1849–1850
   Google Scholar
• . Larger E. Weight gain and insulin treatment. Diabetes Metab. 2005;31(4 Pt 2):4S51–4S56
   Google Scholar
• . Watson L, Wilson BP, Alsop J, Kumar S. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation? Diabetes Obes Metab. 2011;13(9):823–831
   PubMed Web of Science ®Google Scholar
• . Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2011;13(11):1008–1019
   Google Scholar
• . Rosenstock J, Fonseca V, McGill JB,. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. 2009;52(9):1778–1788
   PubMed Web of Science ®Google Scholar
• . Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B, Garber AJ. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med. 2007;18(1):56–62
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086
   PubMed Web of Science ®Google Scholar
• . Holman RR, Farmer AJ, Davies MJ,. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747
   PubMed Web of Science ®Google Scholar
• . Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 2009;52(10):1990–2000
   PubMed Web of Science ®Google Scholar
• . , ORIGIN Trial InvestigatorsGerstein HC, Bosch J,. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328
   PubMed Web of Science ®Google Scholar
• . Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006;23(7):736–742
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes–Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29(3):554–559
   PubMed Web of Science ®Google Scholar
• . Meneghini LF, Traylor L, Schwartz SL. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocr Pract. 2010;16(4):588–599
   PubMed Web of Science ®Google Scholar
• . Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254–259
   PubMed Web of Science ®Google Scholar
• . Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008;371(9618):1073–1084
   PubMed Web of Science ®Google Scholar
• . Blicklé JF, Hancu N, Piletic M,. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study. Diabetes Obes Metab. 2009;11(4):379–386
   PubMed Web of Science ®Google Scholar
• . Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M,. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–451
   PubMed Web of Science ®Google Scholar
• . Aschner P, Chan J, Owens DR,. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012;379(9833):2262–2269
   PubMed Web of Science ®Google Scholar
• . Swinnen SG, Dain MP, Aronson R,. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33(6):1176–1178
   PubMed Web of Science ®Google Scholar
• . Bruce DG, Davis WA, Davis TM. Glycemic control in older subjects with type 2 diabetes mellitus in the Fremantle Diabetes Study. J Am Geriatr Soc. 2000;48(11):1449–1453
   PubMed Web of Science ®Google Scholar
• . Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000;23(2):176–180
   PubMed Web of Science ®Google Scholar
• . Fakhouri TH, Ogden CL, Carroll MD,. Prevalence of obesity among older adults in the United States, 2007–2010. NCHS data brief, no 106. http://www.cdc.gov/nchs/data/databriefs/db106.htm. Accessed June 15, 2014
   Google Scholar
• . Goodpaster BH, Krishnaswami S, Resnick H,. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care. 2003;26(2):372–379
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Skovlund SE, Landgraf R. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin. 2009;25(8):1985–1993
   PubMed Web of Science ®Google Scholar
• . Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26( Suppl 3):S18–S24
   PubMed Web of Science ®Google Scholar
• . Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose medications. Diabet Med. 2009;26(4):416–424
   PubMed Web of Science ®Google Scholar